Northern Trust: Catalyst Pharmaceutical CPRX Historial de posiciones en acciones
Comprado
Mantenidas
Vendido
| Trimestre | Valor de mercado | Estado | Acciones |
Cambio en la posición | Valor operado | Peso en el portafolio | Puesto en el portafolio | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q3 | – | Venta |
-1,330,520
| Cerradas | -USD 41.8 M | – | 4435 |
|
|
2026
Q2 | USD 41.8 M | Compra |
1,330,520
+92,768
| +7% | +USD 2.74 M | ﹤0.01% | 1321 |
|
|
2026
Q1 | USD 30.6 M | Compra |
1,237,752
+25,779
| +2% | +USD 614 k | ﹤0.01% | 1422 |
|
|
2025
Q4 | USD 28.3 M | Venta |
1,211,973
-51,915
| -4% | -USD 1.16 M | ﹤0.01% | 1447 |
|
|
2025
Q3 | USD 24.9 M | Venta |
1,263,888
-11,202
| -0.9% | -USD 230 k | ﹤0.01% | 1542 |
|
|
2025
Q2 | USD 27.7 M | Venta |
1,275,090
-211,108
| -14% | -USD 4.98 M | ﹤0.01% | 1457 |
|
|
2025
Q1 | USD 36 M | Venta |
1,486,198
-17,368
| -1% | -USD 391 k | 0.01% | 1284 |
|
|
2024
Q4 | USD 31.4 M | Compra |
1,503,566
+119,766
| +9% | +USD 2.57 M | ﹤0.01% | 1423 |
|
|
2024
Q3 | USD 27.5 M | Venta |
1,383,800
-2,907
| -0.2% | -USD 53.9 k | ﹤0.01% | 1429 |
|
|
2024
Q2 | USD 21.5 M | Venta |
1,386,707
-43,041
| -3% | -USD 670 k | ﹤0.01% | 1512 |
|
|
2024
Q1 | USD 22.8 M | Compra |
1,429,748
+11,007
| +0.8% | +USD 166 k | ﹤0.01% | 1506 |
|
|
2023
Q4 | USD 23.8 M | Venta |
1,418,741
-18,424
| -1% | -USD 252 k | ﹤0.01% | 1487 |
|
|
2023
Q3 | USD 16.8 M | Compra |
1,437,165
+30,262
| +2% | +USD 405 k | ﹤0.01% | 1672 |
|
|
2023
Q2 | USD 18.9 M | Compra |
1,406,903
+14,248
| +1% | +USD 205 k | ﹤0.01% | 1622 |
|
|
2023
Q1 | USD 23.1 M | Venta |
1,392,655
-1,659
| -0.1% | -USD 27.4 k | ﹤0.01% | 1461 |
|
|
2022
Q4 | USD 25.9 M | Compra |
1,394,314
+27,453
| +2% | +USD 423 k | 0.01% | 1377 |
|
|
2022
Q3 | USD 17.5 M | Compra |
1,366,861
+50,729
| +4% | +USD 601 k | ﹤0.01% | 1584 |
|
|
2022
Q2 | USD 9.23 M | Venta |
1,316,132
-3,761
| -0.3% | -USD 27.6 k | ﹤0.01% | 2088 |
|
|
2022
Q1 | USD 10.9 M | Venta |
1,319,893
-58,547
| -4% | -USD 414 k | ﹤0.01% | 2087 |
|
|
2021
Q4 | USD 9.33 M | Venta |
1,378,440
-47,263
| -3% | -USD 311 k | ﹤0.01% | 2277 |
|
|
2021
Q3 | USD 7.56 M | Compra |
1,425,703
+1,555
| +0.1% | +USD 8.5 k | ﹤0.01% | 2471 |
|
|
2021
Q2 | USD 8.19 M | Compra |
1,424,148
+249,975
| +21% | +USD 1.29 M | ﹤0.01% | 2511 |
|
|
2021
Q1 | USD 5.41 M | Venta |
1,174,173
-78,168
| -6% | -USD 311 k | ﹤0.01% | 2698 |
|
|
2020
Q4 | USD 4.18 M | Venta |
1,252,341
-77,290
| -6% | -USD 260 k | ﹤0.01% | 2782 |
|
|
2020
Q3 | USD 3.95 M | Venta |
1,329,631
-49,069
| -4% | -USD 192 k | ﹤0.01% | 2682 |
|
|
2020
Q2 | USD 6.37 M | Compra |
1,378,700
+147,737
| +12% | +USD 664 k | ﹤0.01% | 2366 |
|
|
2020
Q1 | USD 4.74 M | Venta |
1,230,963
-4,958
| -0.4% | -USD 20.4 k | ﹤0.01% | 2328 |
|
|
2019
Q4 | USD 4.63 M | Compra |
1,235,921
+45,009
| +4% | +USD 210 k | ﹤0.01% | 2629 |
|
|
2019
Q3 | USD 6.32 M | Compra |
1,190,912
+33,170
| +3% | +USD 177 k | ﹤0.01% | 2412 |
|
|
2019
Q2 | USD 4.44 M | Compra |
1,157,742
+30,398
| +3% | +USD 131 k | ﹤0.01% | 2622 |
|
|
2019
Q1 | USD 5.75 M | Venta |
1,127,344
-1,297
| -0.1% | -USD 3.81 k | ﹤0.01% | 2478 |
|
|
2018
Q4 | USD 2.17 M | Venta |
1,128,641
-25,697
| -2% | -USD 73.6 k | ﹤0.01% | 3002 |
|
|
2018
Q3 | USD 4.36 M | Compra |
1,154,338
+46,394
| +4% | +USD 145 k | ﹤0.01% | 2762 |
|
|
2018
Q2 | USD 3.46 M | Compra |
1,107,944
+97,997
| +10% | +USD 297 k | ﹤0.01% | 2899 |
|
|
2018
Q1 | USD 2.41 M | Compra |
1,009,947
+185,639
| +23% | +USD 617 k | ﹤0.01% | 3005 |
|
|
2017
Q4 | USD 3.22 M | Compra |
824,308
+12,795
| +2% | +USD 42.3 k | ﹤0.01% | 2858 |
|
|
2017
Q3 | USD 2.04 M | Compra |
811,513
+8,947
| +1% | +USD 24.5 k | ﹤0.01% | 3160 |
|
|
2017
Q2 | USD 2.22 M | Compra |
802,566
+691,238
| +621% | +USD 1.44 M | ﹤0.01% | 3112 |
|
|
2017
Q1 | USD 217 k | Compra |
111,328
+10,932
| +11% | +USD 13.9 k | ﹤0.01% | 3771 |
|
|
2016
Q4 | USD 105 k | Venta |
100,396
-27,188
| -21% | -USD 31.1 k | ﹤0.01% | 3888 |
|
|
2016
Q3 | USD 139 k | Compra |
127,584
+37,217
| +41% | +USD 33.5 k | ﹤0.01% | 3818 |
|
|
2016
Q2 | USD 64 k | Venta |
90,367
-673,453
| -88% | -USD 542 k | ﹤0.01% | 3975 |
|
|
2016
Q1 | USD 893 k | Venta |
763,820
-288
| -0% | -USD 447 | ﹤0.01% | 3291 |
|
|
2015
Q4 | USD 1.87 M | Compra |
764,108
+595
| +0.1% | +USD 1.7 k | ﹤0.01% | 3095 |
|
|
2015
Q3 | USD 2.29 M | Compra |
763,513
+621,185
| +436% | +USD 2.68 M | ﹤0.01% | 2969 |
|
|
2015
Q2 | USD 588 k | Compra |
142,328
+45,899
| +48% | +USD 183 k | ﹤0.01% | 3519 |
|
|
2015
Q1 | USD 418 k | Venta |
96,429
-525
| -0.5% | -USD 1.89 k | ﹤0.01% | 3657 |
|
|
2014
Q4 | USD 288 k | Compra |
96,954
+7,540
| +8% | +USD 20.7 k | ﹤0.01% | 3704 |
|
|
2014
Q3 | USD 297 k | Venta |
89,414
-2,228
| -2% | -USD 5.82 k | ﹤0.01% | 3715 |
|
|
2014
Q2 | USD 232 k | Compra |
91,642
+14,856
| +19% | +USD 31.7 k | ﹤0.01% | 3816 |
|
|
2014
Q1 | USD 174 k | Compra |
76,786
+10,743
| +16% | +USD 22.5 k | ﹤0.01% | 3821 |
|
|
2013
Q4 | USD 129 k | Compra |
66,043
+10,158
| +18% | +USD 20.5 k | ﹤0.01% | 3818 |
|
|
2013
Q3 | USD 171 k | Compra |
55,885
+12,979
| +30% | +USD 21.8 k | ﹤0.01% | 3696 |
|
|
2013
Q2 | USD 38 k | Compra |
+42,906
| Nuevas | +USD 34.3 k | ﹤0.01% | 3958 |
|
Otros fondos que tienen CPRX en su portafolio
Posición de Northern Trust en CPRX: resumen de T3 2026
Northern Trust liquidó su posición en Catalyst Pharmaceutical (CPRX) en T3 2026: cerró una participación de 1,330,520 acciones, con ventas por un valor estimado de USD 41.8 M.
Northern Trust reportó por primera vez una posición en CPRX en T2 2013 y la mantuvo en 53 trimestres. La posición alcanzó su máximo de USD 41.8 M en T2 2026. Al cierre de T3 2026, 2 fondos que sigue Wall St. Rank mantienen una posición en CPRX.
- Northern Trust reportó que ya no tenía una posición en Catalyst Pharmaceutical al cierre de T3 2026, después de venderla por completo durante el trimestre.
- Northern Trust vendió 1,330,520 acciones de Catalyst Pharmaceutical en T3 2026, por un valor estimado de USD 41.8 M.
- Northern Trust reportó por primera vez una posición en Catalyst Pharmaceutical en T2 2013 y la mantuvo en 53 trimestres.
- La posición de Northern Trust en Catalyst Pharmaceutical alcanzó su máximo de USD 41.8 M en T2 2026.
- Al cierre de T3 2026, 2 fondos que sigue Wall St. Rank tenían Catalyst Pharmaceutical en su portafolio.
Según el informe 13F de Northern Trust correspondiente a T3 2026, presentado el 16 nov 2026.